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Abstract: 
An Alkanna orientalis leaf and flower extract inhibited the growth of Staphylococcus aureus, a 
pathogen that causes an estimated 478000 hospitalizations in the US annually. Bioassay-guided 
fractionation of A. orientalis resulted in isolation of the flavonoid sarothrin (5,7,4′-trihydroxy-
3,6,8-trimethoxyflavone), which inhibited the growth of Mycobacterium smegmatis (MIC 
75 μM) and S. aureus (MIC > 800 μM), and possessed efflux pump inhibitory activity. This is 
the first report of antimicrobial or efflux pump inhibitory activity of sarothrin, and of its presence 
in A. orientalis. Our findings suggest that the effectiveness of A. orientalis extracts is due to a 
combination of multiple constituents, including sarothrin. 
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Article: 
Bacterial infections have an estimated $20 billion burden on the US health care system [1]. 
Botanicals have been suggested as an under-utilized source of antimicrobial agents [2, 3]. With 
this project, our goals were to evaluate the antimicrobial activity of the plant Alkanna orientalis 
(L.) Boiss (Boraginaceae) against Staphylococcus aureus and Mycobacterium smegmatis, and to 
identify compounds that play a role in this activity. A. orientalis was chosen for this study based 
on antimicrobial activity observed for the crude extract by our laboratory and others [4, 5], and 
on the ethnobotanical literature. This plant genus was traditionally employed as a treatment for 
digestive problems [4] and for wound healing. 
 
Bioassay-guided fractionation of Alkanna orientalis resulted in the isolation of the flavonoid 
sarothrin (5,7,4′-trihydroxy-3,6,8-trimethoxyflavone) (Fig. 1). Sarothrin is present in other 
botanicals, including Encelia densifolia (Asteraceae) [6], Ononis rotundifolia (Fabaceae), and 
Gardenia obtusifolia (Rubiaceae) [7]. However, this is the first report of sarothrin in A. orientalis 
or any member of the Boraginaceae family. 
 
Sarothrin was observed to inhibit M. smegmatis (MIC 75 μM) and weakly inhibited S. aureus 
growth [MIC > 800 μM, Table 1, 50% inhibition of growth at 38 μg/mL (100 μM), Fig. 3S]. 
However, the crude A. orientalis leaf and flower extract, which contained only 1.63 ± 0.13% 
sarothrin, had very similar activity to that of sarothrin alone (Fig. 3S). Furthermore, comparisons 
were made of sarothrin concentrations in various A. orientalis plant parts (Table 2). The highest 
levels were extracted from leaves and flowers, while very lowlevels were present in roots and 
seeds (Table 2). Nonetheless, similar antimicrobial activity (30 to 60% inhibition) was observed 
from extracts of various plant parts (Fig. 3S). Collectively, these findings suggest that additional 
constituents besides sarothrin are likely to play a role in the antimicrobial activity of A. 
orientalis. 
 
  
 
Fig. 1 Structure of sarothrin (1) isolated from Alkanna orientalis as a result of bioactivity-
directed fractionation evaluating antimicrobial activity against Staphylococcus aureus. 
 
Table 1. MIC (concentration required to completely inhibit bacterial growth) measured for 
purified sarothrin against two pathogenic bacteria. 
 
Organism  MIC sarothrin (μM)  MIC ciprofloxacin (μM) 
Staphylococcus aureus NCTC 8325–4  > 800  1.5 
Mycobacterium smegmatis ATCC 607  75  6 
 
Table 2. Quantity of the bioactive flavonoid sarothrin in extracts prepared from various plant 
parts of Alkanna orientalis. 
Plant part  Sarothrin concentration (ppm)a ± SD 
Rootb  0.51 ± 0.40 
Seed  0.37 ± 0.12 
Leaf  52.9 ± 1.4 
Flower + leaf  160 ± 13 
aQuantities are reported as mg sarothrin/kg plant material based on LC‑MS analysis of extracts 
prepared from the relevant plant parts. Standard deviations are for triplicate analyses of the same 
extract. Error bars represent ± the standard deviation of each extract concentration based on 
linear regression analysis of a 9 point calibration curve of peak area versus concentration with 
slope (m) = 0.9787 ± 0.0021, intercept (b) = 6.346 ± 0.018, and R2 = 0.9967; 
 b The concentration reported for the root extract is approximate only, as the concentration in the 
extract at the dilution analyzed was below the lower limit of detection for the method. 
Concentrations for the seed, leaf, and flower + leaf extract fell within the linear range of the 
calibration curve. 
 
Efflux pump inhibition in combination with antibiotics has been proposed as a potential 
therapeutic strategy against bacterial infections [3]. Reports indicating efflux pump inhibitory 
activity of flavonoids [8–11] led us to investigate the efflux pump inhibitory activity of sarothrin. 
A fluorescence-based assay was utilized, which relies on the efflux of ethidium bromide driven 
by the S. aureus efflux pump NorA [12]. As is apparent from the data in Fig. 2, sarothrin blocked 
ethidium bromide efflux (data overlaid with the positive control CCCP). These findings suggest 
that sarothrin possesses efflux pump inhibitory activity. This could be relevant to the overall 
effectiveness of A. orientalis extracts against bacteria; while sarothrin is only a weak 
antimicrobial agent alone, it could increase the activity of other antimicrobial compounds in the 
extracts by blocking bacterial efflux pumps. 
 
 
Fig. 2 Percent fluorescence over time for S. aureus (NCTC 8325–4) loaded with ethidium 
bromide and treated with purified sarothrin. The known efflux pump inhibitor CCCP (carbonyl 
cyanide m-chlorophenylhydrazone) served as a positive control. Vehicle consisted of 10% 
DMSO in Müller Hinton broth. Triplicate measurements were made for separate aliquots of 
solution with different S. aureus pellets, and data points represent the average of these three 
measurement. Error bars are ± standard error. Fluorescence measurements were made using λex 
= 530 nm, λem = 600 nm.  
 
Materials and Methods 
 
Staphylococcus aureus (NCTC 8325-4) [13] and Mycobacterium smegmatis (ATCC 607) were 
employed. Müller Hinton broth, carbonyl cyanide m-chlorophenylhydrazone (CCCP), berberine, 
and ciprofloxacinwere purchased from Sigma-Aldrich, all with purity > 98%. 
 
Alkanna orientalis was cultivated at Horizon Herbs and identified by Richard Cech. A voucher 
was deposited in the University of North Carolina Herbarium (NCU 592736). Dried, powdered 
samples from A. orientalis leaves (2.0 g), roots (2.0 g), leaves + flowers (2060 g), or seeds (10.5 
g)were extracted in methanol (1 : 12.5, w/v). Extracts were stirred for 24 hr, filtered and rotary 
evaporated. The residue was separated with liquid/liquid partitioning, as described elsewhere 
[14]. Final yields of the organic fraction were 17.4mg, 7.3mg, 20.3 g, and 1.5mg, respectively, 
for the leaf, root, flower + leaf, and seed extracts. The flower + leaf extract was fractionated over 
silica gel with a hexane: chloroform:methanol gradient as described [15]. The most active 
fraction (strongest inhibition of S. aureus) was separated over silica gel utilizing hexane: ethyl 
acetate as the gradient [15]. Yellow crystals (52.0mg, 92% pure) (sarothrin) precipitated and 
were purified using reversed-phase preparative HPLC with a YMC ODS‑A column (5 μm, 120 
Å; 250 × 20 mm; Waters) with a CH3CN:H2O gradient. Sarothrin (Fig. 1) eluted at 13.5min 
(7.03mg, 97% purity, 0.00034% yield). 
Sarothrin (5,7,4′-trihydroxy-3,6,8-trimethoxyflavone) (1): yellow solid, HRESIMS 361.09100 
[M + H]+ (calcd. for C18H17O8, 361.09 180); 1H NMR (500 MHz acetone-d6) (Fig. 1S) and 
13C NMR (125 MHz, acetone-d6) (Fig. 2S) agreed with literature values (Table 1S) [16]. The 
HRMS and NMR instruments employed were an LTQ-Orbitrap (Thermo) and JEOL ECA-500, 
respectively. Sarothrin quantitation was performed using a triple quadrupole mass spectrometer 
(TSQ Access; Thermo) with positive ion electrospray coupled to an HP1200 HPLC (Agilent) 
with a C-18 Prevail column. An acetonitrile (1% formic acid) :water (1% formic acid) gradient 
was employed at 0.3mL/min. 
 
Mycobacterium smegmatis was grown in Middlebrook 7H9 medium, and MIC values measured 
after 3 days incubation were as described previously [17]. Staphylococcus aureus was grown in 
Müller Hinton broth, MICs measured using CLSI standard methods [18], and efflux pump 
inhibitory activity evaluated, as described previously [15,19]. 
 
Supporting information 
 
NMR data for sarothrin and comparison of S. aureus growth inhibition by various A. orientalis 
extracts are available as Supporting Information. 
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